Skip to main
SER
SER logo

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics Inc is positioned favorably due to its innovative POZ Platform delivery technology, which enhances drug loading control and release precision, addressing market needs in treating neurological diseases and pain. The advancement of pipeline candidates, particularly SER-252, alongside the potential success of SER-270, presents significant upside potential that is currently unaccounted for in the company's valuation assessment. Furthermore, the expanding approval footprint of enFuse suggests a strong likelihood of increased global acceptance for SER-252, which may further enhance Serina Therapeutics’s market position and financial performance in the coming years.

Bears say

Serina Therapeutics reported a consistent net loss of $0.64 per share, indicating ongoing financial challenges for the company. The outlook is further clouded by significant risks, including the potential inability to advance their lead candidate, SER-252, through clinical development, secure necessary regulatory approvals, and achieve anticipated market uptake due to competition and other dynamics. Additionally, there are concerns regarding future partnership opportunities and the risk of dilution, with full-year 2025 net loss estimates increasing substantially to $2.01 from an original forecast of $0.36 per share.

SER has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 2 analysts, SER has a Strong Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.